Digital Ulcer
10
2
2
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
20.0%
2 terminated out of 10 trials
33.3%
-53.2% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (10)
Hand Disability In Systemic Sclerosis - Digital Ulcers
Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis
Effectiveness of the EmoLED Medical Device in the Healing of Digital Ulcers in Patients With Scleroderma.
Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.
Co-designing Digital Ulcers Opportunities With Patients and Clinicians
Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis
Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study
Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers